FDA Clearance Tracker · P030005
CONTAK RENEWAL MODELS H125 AND H120 WITH THE MODEL 2865 VERSION 1.8 APPLICATION SOFTWARE
Last checked: Nov 20, 2026Latest source record: Jan 26, 2004 (this decision)Source: openFDAMethods & limitations
Decided
Jan 26, 2004
Approved
Time to decision
308 days
Received Mar 24, 2003. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P030005
- Device name
- CONTAK RENEWAL MODELS H125 AND H120 WITH THE MODEL 2865 VERSION 1.8 APPLICATION SOFTWARE
- Applicant
- Guidant Corp.
- Applicant location
- St Paul, MN
- Received
- Mar 24, 2003
- Decided
- Jan 26, 2004
- Decision
- Approved
- Supplements
- 244 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE CONTAK RENEWAL TR. THE DEVICE IS INDICATED S FOLLOWS: THE CONTAK RENEWAL TR PULSE GENERATOR IS INDICATED FOR PATIENTS WHO HAVE MODERATE TO SEVERE HEART FAILURE (NYHA CLASS III/IV) INCLUDING LEFT VENTRICULAR DYSFUNCTION (EF <= 35%) AND QRS DURATION >= 120 MS AND REMAIN SYMPTOMATIC DESPITE STABLE, OPTIMAL HEART FAILURE DRUG THERAPY (AS DEFINED IN THE CLINICAL TRIALS SECTION). THE DEVICE PROVIDES ATRIAL-VENTRICULAR TRACKING MODES TO HELP PRESERVE AV SYNCHRONY, AND ADAPTIVE-RATE PACING FOR PATIENTS WHO WOULD BENEFIT FROM ADJUSTED PACING RATES CONCURRENT WITH PHYSICAL ACTIVITY.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code NKE (Pulse generator, pacemaker, implantable, with cardiac resynchronization (CRT-P)).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Guidant Corp.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.